论文部分内容阅读
从人血浆中分离出血管生成抑制素(Angiostatin),并以此进行胃癌转移模型治疗试验,以探讨血管生成抑制素抑制胃癌浸润转移的作用.以Sepharose亲和层析柱从血浆成分中分离出纤溶酶原,再用弹性蛋白酶酶切,经Sepharos 4B-Lysine亲和层析柱分离出血管生成抑制素.以完整组织块裸鼠胃壁内原位种植建立胃癌转移模型,肿瘤种植当天给实验动物24μg(1.2mg/kg)血管生成抑制素腹腔内注射,以后每天给以12μg(0.6mg/kg);以相同剂量的纤溶酶原腹腔内注射作为对照,相同体积的生理盐水腹腔内注射作为空白对照;治疗共进行3周,肿瘤种植后10周处死实验动物,测量肿瘤体积,观察转移情况,免疫组化法检测肿瘤微血管密度.结果:
Angiostatin was isolated from human plasma and used as a model for the treatment of metastasis of gastric cancer to investigate the role of angiostatin in inhibiting the invasion and metastasis of gastric cancer. Separation from plasma components using Sepharose affinity chromatography The plasminogen was digested with elastase and angiostatin was isolated by Sepharos 4B-Lysine affinity column. The gastric cancer metastasis model was established by implanting the intact tissue blocks in situ in the stomach wall of the nude mice. 24 μg (1.2 mg/kg) of angiostatin was intraperitoneally injected into the animal and then given daily at 12 μg (0.6 mg/kg); the same dose of plasminogen was injected intraperitoneally as a control and the same volume of saline was intraperitoneally injected. As a blank control, treatment was performed for a total of 3 weeks, and experimental animals were sacrificed 10 weeks after tumor implantation. Tumor volume was measured and metastasis was observed. Tumor microvessel density was measured by immunohistochemistry.